Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?

MLA

Maria Dalamaga, and Irene Karampela. “Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to Be Beneficial as an Adjunct Treatment in COVID-19?” Archives of Medical Research, vol. 51, Oct. 2020, pp. 741–42. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8eca3aa9c4f88517408050dec306cd7d&authtype=sso&custid=ns315887.

APA

Maria Dalamaga, & Irene Karampela. (2020). Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Archives of Medical Research, 51, 741–742.

Chicago

Maria Dalamaga, and Irene Karampela. 2020. “Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to Be Beneficial as an Adjunct Treatment in COVID-19?” Archives of Medical Research 51 (October): 741–42. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8eca3aa9c4f88517408050dec306cd7d&authtype=sso&custid=ns315887.